WHITEHOUSE STATION, N.J. (AP) — Drugmaker Merck & Co. says the Food and Drug Administration is reviewing its experimental insomnia medication, suvorexant (SOO’vor-eks-ant).
Recommended Stories
Print subscriber? Click here to login/register your account
Digital subscriber? Click here to login/register your account.